Clinical Trials Directory

Trials / Completed

CompletedNCT04540133

Dexamethasone Solution and Dexamethasone in Mucolox™

Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
29 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Topical steroid therapy is considered the first line of treatment for Oral Inflammatory Ulcerative Diseases with current treatment regimens requiring multiple application or rinses daily. Using Mucolox™ as a vehicle to deliver topical dexamethasone to the oral mucosa has the potential to effectively prolong contact time between the medication. The primary objective of this study is to determine the clinical efficacy and tolerability of compound dexamethasone at 0.5 mg/5 mL in Mucolox™ for the treatment of Oral Inflammatory Ulcerative Diseases as measured by a reduction in oral symptoms between patients treated with compounded dexamethasone 0.5mg/5ml solution in Mucolox™ (group A) and patients treated with topical commercial dexamethasone 0.5mg/5ml solution only (group B). and mucosa, leading to improved clinical outcomes due to the need for less frequent application.

Conditions

Interventions

TypeNameDescription
DRUGdexamethasone 0.5mg/5ml solutionPatient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
DRUGdexamethasone 0.5mg/5ml solution in Mucolox™Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate

Timeline

Start date
2020-12-26
Primary completion
2023-01-06
Completion
2023-01-06
First posted
2020-09-07
Last updated
2023-12-15
Results posted
2023-12-15

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04540133. Inclusion in this directory is not an endorsement.